Lantern Pharma Announces First Patient Dosed In The Phase 1 Study For LP-184 in Advanced Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma Inc. (NASDAQ:LTRN) has announced the first patient dosing in the Phase 1 clinical trial for LP-184, a potential therapy for advanced solid tumors. The drug, developed with Lantern's AI Platform, RADR®, has a global aggregate market potential of approximately $11-13 billion. The Phase 1 trial is assessing the safety and tolerability of escalating doses of LP-184 in patients with advanced solid tumors and recurrent high-grade gliomas. Lantern plans to advance LP-184 into additional clinical trials after the Phase 1 trial.
September 25, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantern Pharma's announcement of the first patient dosing in the Phase 1 clinical trial for LP-184 could potentially boost investor confidence in the company's ability to develop and bring to market new therapies. The estimated market potential of $11-13 billion for LP-184 also indicates significant revenue potential for the company if the drug is successful.
The commencement of the Phase 1 clinical trial for LP-184 is a significant milestone for Lantern Pharma, indicating progress in the company's drug development pipeline. This could potentially boost investor confidence in the company's ability to develop and bring to market new therapies. Furthermore, the estimated market potential of $11-13 billion for LP-184 indicates significant revenue potential for the company if the drug is successful. However, it's important to note that the drug is still in the early stages of clinical trials, and its success is not guaranteed.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100